) have led to the identification of causative mutations in 11 genes implicated in monogenic typical or atypical forms of parkinsonism. From these, eight genes have been associated with autosomal-recessive patterns of inheritance, either causing typical early-onset PD (PARK2, PINK1, and DJ-1/PARK7) or atypical forms of parkinsonism with juvenile onsets (ATP13A2, PLA2G6, FBXO7, DNAJC6, and SYNJ1). Three genes have been shown to cause typical autosomal dominant PD phenotypes (SNCA, LRRK2, and VPS35) associated with early-or late-onsets of disease. Additionally, other genes are known to harbor mutations associated with non-PD disorders that may present with parkinsonism, for example ATXN2, ATXN3, GCH1, GRN, MAPT, C9ORF72, CSF1R, TH, and SPG1. Very recently, mutations in RAB39B have been described as causing X-linked intellectual disability plus a phenotype indistinguishable from early-onset PD.
Other chromosomal loci (like PARK3 and PARK10, for example) have been identified by genome-wide approaches as genomic regions associated with typical PD. These loci may contain other, still-to-be-identified, PD genes.
Lastly, there are also some genes that have been suggested to harbor causative PD mutations, which have not been confirmed: GIGYF2, HTRA2, UCHL1, EIF4G1, and SPR. By using genetic family studies (for LRRK2) and a candidate gene approach (for GBA), high-risk variants (with odds ratio in the range of 5-8) for the development of typical PD have been identified in both genes (central part of the graph).
More recently, the development of whole-genome genotyping platforms (pink area of the graph) has allowed for the study of the involvement of common variants with low risk in the disease. This has led to the identification of 24 new genetic loci by several independent genome-wide association studies (GWAS) and meta-analyses: SNCA, LRRK2, MAPT, RAB7L1, BST1, GAK, ACMSD, STK39, MCCC1, SYT11, CCDC62, FGF20, STX1B, GPNMB, SIPA1L2, INPP5F, MIR4697HG, GCH1, VPS13C, SCARB2, RIT2, DDRGK1, and SREBF1 . Because of the way these studies are designed, they only identify genetic regions associated with disease and not specific genes or variants. For this reason, if the significant single nucleotide polymorphisms (SNPs) are intergenic or the region contains more than one gene, the locus usually gets its name from the gene closest to the significant hit. Very few of these significant hits have a clear functional role in the disease and, because of this, follow-up work is currently underway to determine exactly which genes and genetic variants are important for the disease and how they are exerting their effect. Recently, an unbiased screen for interactors of LRRK2 identified the most likely candidates for two of these GWAS loci: in chromosome 1q32, the associated locus (originally named RAB7L1/NUCKS1) contained five genes, and in chromosome 4p16, the associated locus (originally named GAK/TMEM175/DGKQ) contained nearly ten genes. RAB7L1 and GAK have now been identified as LRRK2 interactors and, in this way, as the most likely hits in each region. Additionally, these proteins were shown to form a newly identified protein complex that promotes clearance of Golgi-derived vesicles via the autophagy-lysosome system both in vitro and in vivo, clearly highlighting the role the "Autophagy/Lysosomal degradation" pathway in Parkinson's disease.
More generally, pathway analyses of GWAS data implicated other biological processes as primary etiological events in the disease with significant overrepresentation of association signals in pathways related to "regulation of leucocyte/lymphocyte activity," "cytokine-mediated signaling," "axonal guidance," "focal adhesion," and "calcium signaling."
Representation of genes within each group in the graph is approximate and does not reflect differences in frequency or risk. 
